COMPANY
Pliant Therapeutics
Pliant Therapeutics's website says: "Our lead drug candidate, PLN-101095, is an αvβ8 /αvβ1 integrin inhibitor currently being investigated in the FORTIFY trial for people with advanced or metastatic solid tumors." From company website Source · Oct 13, 2026
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Vice President, Regulatory Affairs and Quality (GxP) | South San Francisco, CA | Aug 27, 2026 | Oct 8, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (1 open job at last check). source ↗
- Trial start Phase 2: Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis source ↗
- Trial start 1: A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors source ↗
- Trial start Phase 2: Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) source ↗
- Trial start Phase 2: Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 source ↗
- Trial start 2: Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) source ↗
- Trial start Phase 2: Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis source ↗
- Trial start 2: Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ source ↗
Upcoming milestones
- 2030-06 (ESTIMATED) · 1 · A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors · NCT06270706
Open jobs 1
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Vice President, Regulatory Affairs and Quality (GxP) | South San Francisco, CA | Aug 27, 2026 | Oct 8, 2026 | Executive |
Clinical trials (lead sponsor) 7
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT06270706 | A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | 1 | Recruiting | Aug 30, 2023 | 2030-06 (estimated) |
| NCT06097260 | Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis | Phase 2 | Terminated | Nov 16, 2023 | Apr 4, 2025 (actual) |
| NCT04480840 | Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) | 2 | Completed | Jul 27, 2020 | Feb 26, 2024 (actual) |
| NCT05621252 | Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809) | Phase 2 | Completed | Jul 13, 2022 | Dec 27, 2023 (actual) |
| NCT04396756 | Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis | Phase 2 | Completed | Mar 3, 2020 | Feb 1, 2023 (actual) |
| NCT04072315 | Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/ | 2 | Completed | Feb 13, 2020 | Jun 27, 2022 (actual) |
| NCT04565249 | Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19 | Phase 2 | Terminated | Oct 22, 2020 | Jun 1, 2021 (actual) |
Connect
See your connections at Pliant Therapeutics on LinkedIn (search by name, results not checked)